PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. 

Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
net income	-9.22M -	-10.25M 11.14%	-23.85M 132.71%	-39.25M 64.59%	-98.56M 151.14%	-131.07K 99.87%
depreciation and amortization	92K -	96K 4.35%	105K 9.38%	174K 65.71%	508K 191.95%	1.79M 252.95%
deferred income tax
stock based compensation	160K -	77K 51.88%	332K 331.17%	1.42M 328.01%	2.24M 57.42%	2.27M 1.39%
change in working capital	-468K -	66K 114.10%	2.03M 2,971.21%	-2.44M 220.47%	-4.26M 74.53%	29.37M 789.07%
accounts receivables					1.23M -
inventory					-31.66M -
accounts payables	-344K -	-213K 38.08%	1.34M 727.70%	802K 40.01%	974K 21.45%	9.01M 825.05%
other working capital	-124K -	279K 325%	690K 147.31%	-3.24M 570.14%	25.19M 876.48%	20.36M 19.18%
other non cash items	-252K -	1.75M 794.05%	4.33M 147.51%	500K 88.45%	40.13M 7,925%	-80.71M 301.16%
net cash provided by operating activities	-9.69M -	-8.26M 14.75%	-17.05M 106.48%	-39.59M 132.18%	-59.96M 51.43%	-47.42M 20.92%
investments in property plant and equipment	-94K -	-216K 129.79%	-119K 44.91%	-960K 706.72%	-1.41M 47.08%	-2.68M 89.73%
acquisitions net
purchases of investments	-1.60M -
sales maturities of investments	10.95M -
other investing activites	-8K -
net cash used for investing activites	9.25M -	-216K 102.34%	-119K 44.91%	-960K 706.72%	-1.41M 47.08%	-2.68M 89.73%
debt repayment				-938K -	-2.73M 190.72%	-5.46M 100.04%
common stock issued			42.97M -	46.28M 7.69%	2.94M 93.64%	60.35M 1,951.46%
common stock repurchased
dividends paid
other financing activites	1K -	18.17M 1,816,500%	21.82M 20.13%	8.19M 62.48%	15.25M 86.24%	8.87M 41.81%
net cash used provided by financing activities	1K -	18.17M 1,816,500%	64.80M 256.69%	53.53M 17.39%	15.47M 71.11%	63.77M 312.34%
effect of forex changes on cash
net change in cash	-438K -	9.69M 2,312.56%	47.63M 391.44%	12.97M 72.76%	-45.90M 453.81%	13.68M 129.80%
cash at beginning of period	4.15M -	3.71M 10.55%	13.43M 261.40%	61.05M 354.72%	74.03M 21.25%	28.12M 62.01%
cash at end of period	3.71M -	13.41M 260.86%	61.05M 355.40%	74.03M 21.25%	28.12M 62.01%	41.80M 48.64%
operating cash flow	-9.69M -	-8.26M 14.75%	-17.05M 106.48%	-39.59M 132.18%	-59.96M 51.43%	-47.42M 20.92%
capital expenditure	-94K -	-216K 129.79%	-119K 44.91%	-960K 706.72%	-1.41M 47.08%	-2.68M 89.73%
free cash flow	-9.78M -	-8.47M 13.36%	-17.17M 102.62%	-40.55M 136.16%	-61.37M 51.33%	-50.09M 18.37%

COM:PHASEBIO

PhaseBio Pharmaceuticals, Inc.

Last Close

0.07

17/09 20:00

Volume Today

8.56M

Avg: -

Preview